{"indexed":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T17:08:40Z","timestamp":1550336920602},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1","start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"delay-in-days":1506,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1111\/j.1751-7176.2011.00484.x","type":"article-journal","created":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T09:33:26Z","timestamp":1310981606000},"page":"783-784","source":"Crossref","is-referenced-by-count":0,"title":"Spironolactone Revisited","prefix":"10.1111","volume":"13","author":[{"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[]},{"given":"Jannis","family":"Kountouras","sequence":"additional","affiliation":[]},{"given":"Christos","family":"Zavos","sequence":"additional","affiliation":[]},{"given":"Georgia","family":"Deretzi","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2011,7,18]]},"reference":[{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1751-7176.2010.00339.x","article-title":"Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome","volume":"12","author":"Costa","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB2|cit2","author":"Polyzos","year":"2011","article-title":"Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease","journal-title":"J Renin Angiotensin Aldosterone Syst","DOI":"10.1177\/1470320311402110","doi-asserted-by":"crossref"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/156652409787847191","article-title":"Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines","volume":"72","author":"Polyzos","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","article-title":"Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet","volume":"151","author":"Wada","year":"2010","journal-title":"Endocrinology"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/10641960903407017","article-title":"Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker","volume":"31","author":"Yutaka","year":"2009","journal-title":"Clin Exp Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/0002-9149(88)90551-6","article-title":"Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension","volume":"62","author":"Jeunemaitre","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.0954-6820.1983.tb03684.x","article-title":"The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives","volume":"213","author":"Falch","year":"1983","journal-title":"Acta Med Scand"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF03345529","article-title":"Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile","volume":"28","author":"Zulian","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB10|cit10","author":"Kebapcilar","year":"2009","article-title":"Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome","journal-title":"Arch Gynecol Obstet"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2009.03483.x","article-title":"Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism","volume":"68","author":"Nakhjavani","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EJE-10-0709","article-title":"Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome","volume":"164","author":"Studen","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/j.1552-4604.1991.tb01903.x","article-title":"Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension","volume":"31","author":"Garca","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4158\/EP.14.8.985","article-title":"Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors","volume":"14","author":"Davidson","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5414\/CNP72449","article-title":"Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage","volume":"72","author":"Bomback","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1111\/j.1751-7176.2011.00484.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCHEARTFAILURE.108.821199","article-title":"Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?","volume":"2","author":"Bansal","year":"2009","journal-title":"Circ Heart Fail"}],"container-title":"The Journal of Clinical Hypertension","original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1751-7176.2011.00484.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T03:18:29Z","timestamp":1497928709000},"score":1.0,"subtitle":["LETTER TO THE EDITOR"],"short-title":[],"issued":{"date-parts":[[2011,7,18]]},"references-count":17,"journal-issue":{"published-print":{"date-parts":[[2011,10]]},"issue":"10"},"URL":"http:\/\/dx.doi.org\/10.1111\/j.1751-7176.2011.00484.x","relation":{"cites":[]},"ISSN":["1524-6175"],"subject":["Internal Medicine","Endocrinology, Diabetes and Metabolism","Cardiology and Cardiovascular Medicine"]}